Translate page

NICE - National Institute for Health and Care Excellence

NICE Guidance: Asciminib for treating myeloid leukemia after 2 or more tyrosine kinase inhibitors
Published August 2022

Click here to view the full guidance

Click 'Read more'  to find more NICE guidances